SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending as the community debates its outlook ahead of earnings, with the stock drawing heavy interest from traders tracking its Pro segment performance and macro correlations to interest rates. Investors are actively weighing the impact of cooling consumer demand against potential upside from technical oversold signals and expected stability in dividend-paying assets.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings is trending as investors react to a strong quarterly earnings report that featured a revenue beat and raised guidance, fueling community optimism around its AI-driven growth. Despite the positive results, active discussion reflects frustration with ongoing share price volatility and short-term selling pressure, while long-term supporters remain focused on the company's expanding enterprise partnerships and AI-powered platform adoption.

Energy Vault Holdings, Inc. engages in the provision of energy storage solutions. The company was founded in September 2020 and is headquartered in Westlake Village, CA.

Energy Vault Holdings Inc

Energy Vault is currently trending as investors focus on recent strategic partnership announcements, including a major development agreement in South Africa and expansion into AI-dedicated infrastructure. While the community is actively debating the company's long-term potential versus concerns regarding dilution and volatility, sentiment remains split between bullish technical setups and frustration over recent market performance.

Dominion Energy, Inc. engages in the production and distribution of energy. It operates through following business segments: Dominion Energy Virginia, Dominion Energy South Carolina, Contracted Energy, and Corporate and Other. The Corporate and Other segment focuses on corporate, service company, non-controlling interest in Dominion privatization, and non-regulated retail energy marketing operations. The company was founded by William W. Berry in 1983 and is headquartered in Richmond, VA.

Dominion Energy Inc

Dominion Energy is trending following a significant merger agreement with NextEra Energy, creating a global utility powerhouse designed to meet surging power demand from AI data centers. The community is actively debating the deal's regulatory feasibility, the potential impact on customer electricity rates, and whether the all-stock transaction represents a bargain or an overextension.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is experiencing significant volatility and high trading volume as investors debate its valuation relative to larger semiconductor testing peers. The community is sharply divided, with some highlighting recent contract wins and capacity expansion as signs of a long-term rerating, while others caution against the stock's parabolic move and potential for a sharp reversal.

Amer Sports, Inc. engages in manufacturing, marketing, and selling sports equipment, apparel, and footwear. It operates through the following segments: Technical Apparel, Outdoor Performance, and Ball and Racquet Sports. The Technical Apparel segment refers to outdoor apparel, footwear, and accessories. It includes the Arc’teryx and Peak Performance brands. The Outdoor Performance segment focuses on outdoor apparel, footwear, accessories, and winter sports equipment. It includes the Salomon, Atomic, Armada, and ENVE brands. The Ball and Racquet Sports segment relates to sports equipment, apparel, and accessories. It includes the Wilson, Louisville Slugger, DeMarini, EvoShield, Atec, and Luxilon brands. The company was founded on January 03, 2020 and is headquartered in Helsinki, Finland.

Amer Sports Inc.

Amer Sports is trending as investors react to a strong quarterly earnings report that featured revenue growth and an upward revision to full-year guidance. The community is actively discussing the company's impressive profit margins, its portfolio of premium outdoor brands like Arc'teryx, and contrasting its performance with other consumer discretionary peers.

Agilysys, Inc. operates as a technology company. It offers innovative software for point-of-sale, payment gateway, reservation and table management, guest offers management, property management, inventory and procurement, analytics, document management, and mobile and wireless solutions and services to the hospitality industry. The firm also serves the gaming industry for both corporate and tribal, hotels resort and cruise, foodservice management, and the restaurant, university, and healthcare sectors. The company was founded in 1963 and is headquartered in Alpharetta, GA.

Agilysys, Inc

Agilysys is trending following a strong quarterly earnings report that featured a revenue beat and upward-revised forward guidance, fueling investor confidence in its subscription model and enterprise technology. The community is actively discussing the company's growth trajectory and momentum within the hospitality software sector, with many participants monitoring the stock for potential breakouts.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh its aggressive expansion into AI infrastructure and data centers against regulatory headwinds, specifically recent political proposals aimed at limiting institutional investment in residential real estate. While the stock faces near-term volatility from these policy risks, market participants remain focused on the company's massive dry powder and its pivotal role in financing the next wave of global AI compute capacity.

MakeMyTrip Ltd. engages in the provision of travel services. It offers air ticketing, hotels and packages, rail tickets, bus tickets, car hire, experiences and ancillary travel requirements such as foreign currency exchange services, visa processing, facilitating access to travel, and other insurance products. The company was founded by Deep Kalra and Rajesh Magow on April 28, 2000 and is headquartered in Gurgaon, India.

MakeMyTrip Ltd

MakeMyTrip is trending as investors monitor the company's strong category leadership and massive growth potential within India's expanding travel market, often drawing comparisons to other dominant global online travel agencies. While the stock has seen notable momentum and breakout patterns following solid earnings results, the community remains actively divided between those highlighting long-term structural tailwinds and those cautious of potential overvaluation or broader macroeconomic headwinds.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending as investors digest the company's recent expansion of its U.S. manufacturing infrastructure and its active pursuit of a harmonized global listing on the New York Stock Exchange. Community discourse remains focused on the drugmaker's robust oncology pipeline and its strategic positioning in competitive markets like obesity and hypertension.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Canaccord Genuity Group Raises Sagimet Biosciences (NASDAQ:SGMT) Price Target to $49.00

Canaccord Genuity Group raised their target price on Sagimet Biosciences from $28.00 to $49.00 and gave the stock a 'buy' rating in a research note on Monday...

Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise

Sagimet Biosciences (NASDAQ:SGMT) said it is sharpening its strategic focus on developing differentiated therapies for patients with moderate to severe acne, with plans to advance its lead fatty acid...

Guggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00

Guggenheim cut their target price on Sagimet Biosciences from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday...

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with technicals showing strong momentum.read more...

Why Sagimet Biosciences Stock Is Soaring Today

Key PointsSagimet Biosciences is developing a handful of drugs, but its priority is acne therapies...

Biotech Breakthroughs and Energy Deals Send These Stocks Soaring

A powerful wave of dealmaking, clinical breakthroughs, and infrastructure buildouts is driving renewed momentum with companies spanning energy, biotech, semiconductors, and AI ecosystems delivering headline-making developments. $USEG, $QUIK, $KBLB, $YAAS, $SGMT, $DKI, $GLND

<ul class="summary-bullets"><li>Sagimet plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026 following positive late-stage results in China, which showed a favorable safety profile.</li><li>The biotech firm priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, a 2.4% premium over its closing price on Friday.</li><li>Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028.</li></ul>Shares of Sagimet Biosciences (SGMT) jumped more than 40% on Monday, breaking the 200-day moving average for the first time since early February, after the company priced its latest share offering at a premium and reported positive progress on its acne drug.<a href="https://stocktwits.com/symbol/SGMT">SGMT shares</a> recorded their biggest intraday gains in more than 27 months, rising to their highest levels in over 5 months.<img src="https://news.stocktwits-cdn.com/SGMT_jpg_9df53f672c.webp" alt="SGMT.jpg">Source: TradingView<h2 class="st-heading-2">$175M Offering To Boost Acne Treatment Pipeline</h2>Sagimet priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, aiming to raise roughly $175 million in gross proceeds. This represented a 2.4% premium to the stock’s closing price on Friday. The offering is expected to close around April 28, 2026.The clinical-stage biotech firm plans to use the funds to advance its pipeline, including a Phase 3 trial of its lead drug candidate Denifanstat for acne. Proceeds will also support the development of TVB-3567, a small-molecule inhibitor of fatty acid synthase (FASN) for acne treatment.Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028, including key trial readouts. The remaining funds will be used for general corporate purposes, including clinical development, working capital, and operating expenses.<h2 class="st-heading-2">Denisfanstat Acne Treatment In Focus</h2>Sagimet is advancing its acne treatment pipeline, with plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026. The move follows positive late-stage results in China, where the once-daily oral therapy showed good safety and sustained improvement in patients with moderate to severe acne.The company is also progressing its broader pipeline. Sagiment announced plans to move its TVB-3567, currently in a Phase 1 trial, into Phase 2 studies later this year. Meanwhile, development in metabolic dysfunction-associated steatohepatitis (MASH) is expected to be paused until the company secures non-dilutive funding.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes on the platform remained ‘extremely high.’One user said the company’s acne treatment “has blockbuster potential.”<stembedurl>https://stocktwits.com/Expharmaguy/message/651485936</stembedurl>Another user said SGMT is “now a $50-100 value stock” given the “resoundingly positive phase 3” trial.<stembedurl>https://stocktwits.com/Market_Max/message/651490482</stembedurl>The stock has gained around 40% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-elon-musk-pay-package-share-registration-what-it-means/cZBNYDmReP3">TSLA Stock In Spotlight As EV Maker Registers Shares Tied To Elon Musk’s 2018 Pay Package – Retail Sees Imminent Sell-Off</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?

The firm announced positive late-stage results in China for its lead drug candidate to treat acne, and priced its $175M offering at a premium. 

Equity

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMT News

SGMTSagimet Biosciences Inc